Survodutide or Mazdutide: A Designed Ratio Against an Inherited One

Survodutide and mazdutide hit an identical pair of targets — GLP-1R and the glucagon receptor — but they come from very different starting points. Survodutide (code BI 456906) is a lipidated sequence designed from scratch so that its relative potency at the two receptors hits a chosen ratio. Mazdutide (also listed as IBI362 or LY3305677) is a longer-lived version of oxyntomodulin, the proglucagon-derived hormone that is dual-acting by nature. Comparing survodutide with mazdutide is therefore not about which receptors are involved; it is about how activity is distributed between them, and whether an engineered balance behaves differently from one that evolved.

Each is stocked here as sealed lyophilized powder at three fill weights — 5, 10 and 20 mg — every vial accompanied by its own HPLC certificate; look for survodutide and mazdutide under GLP-1 and incretin peptides. Neither is a medicine: both are research chemicals meant for in-vitro and preclinical laboratory use.

The rationale for a glucagon arm

A GLP-1-only analogue works on one axis: in published studies, GLP-1R activation is linked to reduced feeding, slower gastric emptying and insulin secretion that depends on glucose. Adding glucagon receptor activity brings in a quite separate group of readouts — how the liver processes substrates, ketone body production, lipid mobilisation and, in rodent calorimetry, higher energy expenditure. The stated rationale for both molecules is a division of labour: the incretin component lowers intake, the glucagon component supplies the expenditure and liver effects, and the incretin side also offsets the blood-glucose rise that glucagon receptor stimulation would otherwise cause.

So much they share. Where they diverge is in how each balance was reached. Survodutide is a purpose-built dual agonist whose sequence was optimised to land on a target potency ratio, making that ratio an intentional parameter. Mazdutide retains the oxyntomodulin template, so its ratio is inherited rather than selected and the molecule is altered only enough to survive in circulation. For a laboratory assembling a structure-activity series, that contrast is the experiment.

Structure and stabilisation

Native oxyntomodulin is a 37-amino-acid proglucagon fragment that activates both receptors but is cleared in minutes, mainly through DPP-4 cleavage and filtration by the kidney. Mazdutide carries substitutions that slow that cleavage and a fatty-acid side chain that lets it ride on albumin — the lipidation strategy now standard across modern incretin analogues. Survodutide uses the same general approach of acylation for albumin binding, but on a sequence that is not a direct copy of any single natural hormone.

For practical handling, the lipid chain matters more than the sequence differences. Each molecule is amphipathic with a hydrophobic tail, so at low aqueous concentrations each behaves almost like a detergent — and sticking to glass or polypropylene is the usual explanation when either compound seems to lose potency in a cell assay for no obvious reason. Verify the concentration before assuming that a stock-preparation method validated for one compound works for the other.

The evidence base for each

The human data for both come from the sponsors' investigational trial programmes — regulated studies of pharmaceutical-grade product given under medical supervision. None of it applies to research-grade material bought as a reagent, and nothing on this page suggests otherwise.

For anyone using these as reagents, the relevant evidence is preclinical and in vitro. With both compounds, that typically means: cAMP assays in cells expressing human GCGR or human GLP-1R on their own, to establish the ratio of potencies; arrestin-recruitment assays, where incretin researchers report meaningful bias differences from one analogue to the next; liver and fat-cell models, in which glucagon-dependent outputs such as hepatic glucose release, ketogenesis and lipid content can be measured separately from any effect on feeding; and rodent energy-balance work that pairs intake measurement with calorimetry. Survodutide also appears in preclinical studies with liver-focused endpoints, consistent with its stronger glucagon arm, while mazdutide tends to feature in papers built around its oxyntomodulin ancestry.

Matching compound to question

Pick survodutide if glucagon signalling is what you are varying

If your study is probing how much glucagon activity a design can tolerate before glucose or liver readouts turn unfavourable, survodutide gives more information, because its glucagon component was the central design target. It is also the logical reference when working on a triple agonist like retatrutide: to see what GIP contributes on top of GLP-1 plus glucagon, you need a compound that provides exactly that two-receptor baseline, and survodutide does.

Pick mazdutide if the natural hormone is the reference point

For hypotheses about oxyntomodulin itself — is the ratio found in nature functionally special, and can a stabilised version of the natural peptide match what purpose-designed molecules do? — mazdutide is the appropriate choice, since it preserves that template. It is also the stronger comparator for a group developing its own oxyntomodulin-based sequences that needs a well-characterised reference from the same structural lineage.

Use both if the balance is what you want to study

Many studies end up using the pair. Two agonists that share receptors but differ in balance give you two points on a curve; add a GLP-1-only compound such as semaglutide as the point with no glucagon activity, and you have three. With that set, an effect can be assigned to glucagon receptor signalling rather than to the incretin component — something no experiment with a single compound can do. Both are offered as 5, 10 and 20 mg vials, which makes preparing equimolar parallel stocks easy.

Handling, reconstitution and storage

Their properties are close enough that a single lab protocol usually covers both, with the exceptions noted below. Store unopened freeze-dried vials in the freezer, and allow each to reach room temperature before opening so that moisture from the air does not condense on cold powder. When reconstituting, run the diluent down the inside wall instead of onto the cake, then let the peptide dissolve undisturbed; shaking a lipidated peptide causes foaming and denaturation at the air–liquid interface.

Working out a concentration is bench arithmetic, not a usage instruction. Add 2 mL of diluent to a 10 mg vial and you get 5 mg/mL; 0.1 mL of it contains 500 mcg of peptide. The calculation is the same for either compound, but in both cases the stated vial mass includes counter-ion and residual moisture, so the actual peptide amount is lower than the label implies — and the gap may differ between the two molecules. For quantitative comparisons, work from a measured concentration rather than the label figure. The reconstitution and storage guides give the complete method, and dividing each stock into single-use aliquots spares it from freeze–thaw damage.

Purity, identity and certificate checks

Each vial should come with a certificate for its lot; check that it shows three things. First, HPLC purity backed by an actual chromatogram, not just a number. Second, a mass-spec result that matches the expected mass of the lipidated peptide. Third, a lot number identical to the one on your vial. For lipidated dual agonists, the impurities worth watching are peaks eluting late — possibly leftover side products from the acylation step — and any evidence of des-acyl material, which has the right sequence but lacks the albumin-binding chain that governs how long the molecule persists. Our guide to reading a COA describes what each part of the certificate should show.

Regulatory framing

Investigational status applies to each of them. No authorisation as a medicine exists in the EU or the United States, and material from us carries a laboratory-use-only label. Whatever clinical figures have been reported come from sponsor-run trials conducted with pharmaceutical product under supervision, cited here only to sketch the state of the published record. Our weight-management research overview places these molecules in their wider metabolic context.